Health System

Panelists of a keynote session at AHIP 2022 discuss how lessons learned from investment and infrastructure in public health during the COVID-19 pandemic can be leveraged to promote equitable care for all Americans and prepare for the next public health emergency.

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.

In the first of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses the future of value-based care for the practice as the Oncology Care Model comes to an end today. This week, CMS announced it will launch a successor model.

The utility of value-based frameworks for payers, providers, and those involved in kidney care delivery was addressed during a session at AHIP 2022.

Neighborhood characteristics, race, and ethnicity were found to be risk factors for developing asthma in childhood, suggesting inequities in children’s respiratory health.

Two stakeholders involved in investment and development of behavioral care services discuss the potential of digital therapeutics as a cost-effective alternative to address unmet mental health needs during an AHIP 2022 session.

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging current guidelines.

Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.

Panelists of an AHIP 2022 session discussed how future policy, infrastructure, and investment strategies in public health will reinforce the efforts already made during the pandemic, with partnerships and engagement key to optimize innovation.

Reversing a landmark precedent, the Supreme Court voted Friday to overturn 1973’s Roe v Wade decision that guaranteed American women the constitutional right to an abortion, and at least 1 justice suggested that other precedents, such as the right to birth control, be reversed as well.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Community engagement, investment, and quality metrics were spotlighted as potential solutions to address health inequities affecting marginalized communities nationwide.

An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.

The adequate safety and improved symptom burden observed with self-administration of biologic therapies at home for the management of severe asthma and chronic rhinosinusitis with nasal polyps suggests potential in shifting care away from the more costlier in-patient setting.

Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.

A scalable health system–wide emergency physician education and feedback initiative was associated with decreased opioid prescribing, in excess of background temporal decline.

Data from menstrual tracking apps may be used against people in certain states if Roe v Wade is overturned; 100 million Americans, including 41% of adults, have health care debt; Express Scripts reported results of its program to lower diabetes-related costs.

Recommendations discuss appropriate use and diagnostic, prognostic, and therapeutic implications of cardiac genetic testing, including guidance on impact of exercise.

Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.

Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.

As value realization eludes integrated practice units (IPUs), the authors examine 6 key value drivers for IPU teams to competitively drive volumes and hone their multidisciplinary competencies.

Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.

The Supreme Court has ruled that HHS' decision to lower reimbursement rates to hospitals so that those in the 340B program received reduced rates because they received discounted drugs was unlawful.

The authors’ organization optimized scheduling techniques that improved patient access to pediatric specialists to within 7 calendar days for new patients.

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.

Swaminathan P. Iyer, MD, of the University of Texas MD Anderson Cancer Center, explains the mechanism of action and efficacy/safety observed in phase 1 results of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory T-cell lymphoma.

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Ashok Subramanian, MBA, founder and chief executive officer, Centivo, speaks on the limitations of traditional employer-based health benefit plans in the pursuit of value-based care and what employers should consider in designing these incentives on a community level.

The Federal Trade Commission (FTC) launched an inquiry into the practices of pharmacy benefit managers; FDA advisers overwhelmingly support approval of Novavax, a new COVID-19 vaccine; drug prices soar to 20% annual inflation.